Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Weekly Wrap 24 August

Julia Lee
August 24, 2018

Market Update 23 August

Julia Lee
August 23, 2018

Weekly Wrap 17 August

Julia Lee
August 17, 2018

Equity Investor 13 August

Julia Lee
August 14, 2018

Equity Investor 6 August

Julia Lee
August 7, 2018

Market Update

Julia Lee
August 2, 2018

Equity Investor

Julia Lee
July 31, 2018

Equity Investor

Julia Lee
July 24, 2018

Market Update

Julia Lee
July 23, 2018

10 favoured stocks

Bell Direct
July 17, 2018